![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
4.50 | 0.28% | 1,599.50 | 1,604.00 | 1,605.00 | 1,612.50 | 1,591.00 | 1,600.50 | 5,248,767 | 16:35:05 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.40 | 66.06B |
Date | Subject | Author | Discuss |
---|---|---|---|
15/3/2024 13:59 | Today is particularly disappointing at present ..... ;0( | tradermichael | |
15/3/2024 13:58 | Fall due to the rkt litigation decision in the US ? | ![]() panache1 | |
15/3/2024 13:37 | I know I shouldn't be, but slightly frustrated that it seems rangebound at the moment. News flow has been very good the past few months and hopefully that will continue! | ![]() rikky72 | |
13/3/2024 20:48 | More than! | ![]() patientcapital | |
13/3/2024 15:56 | It will be interesting if GSK can do AZN over the next several years, shareprice wise... 🤞 | ![]() igoe104 | |
13/3/2024 15:42 | Looking good here 2024 a good year for gsk | ![]() supermarky | |
13/3/2024 13:18 | M. Fool asserts: Even before the latest announcements, GSK looked undervalued compared to its peers. On the key price-to-earnings (P/E) ratio measurement, it currently trades at just 13.8 against a peer group average of 25.3. A discounted cash flow analysis shows GSK shares to be around 58% undervalued at their current price of £16.81. Therefore, a fair value would be around £40.00. | tradermichael | |
13/3/2024 09:43 | Deutsche Bank reissued their buy rating on shares of GSK (LON:GSK) in a research note published on Tuesday. Deutsche Bank currently has a GBX 1,950 target price on the stock. | tradermichael | |
11/3/2024 14:28 | Still very cheap ..... ;0) | tradermichael | |
08/3/2024 17:03 | Sterling's relative strength not helping Dollar earnings. Some profit taking perhaps. Still cheap though. | ![]() patientcapital | |
08/3/2024 13:01 | You can't have pancakes every day | abdullla | |
08/3/2024 12:46 | Why the fall today ? | ![]() alibizzle | |
07/3/2024 22:18 | Including the Haleon shares we are not far behind. | ![]() pcok | |
07/3/2024 15:42 | She deserves her 50% increase this year .... ;0) | tradermichael | |
07/3/2024 11:43 | Great RNS. Good share price reaction so far. Any of the usual suspects want a pop at our incompetent CEO today? The silence is deafening. | ![]() pcok | |
07/3/2024 10:22 | Novo Nordisk also having a big up day if you're following the granolas | ![]() dplewis1 | |
07/3/2024 10:19 | Hopefully 1800 coming with a bit of luck | ![]() supermarky | |
07/3/2024 09:26 | back above where we should be.. | ![]() lippy4 | |
07/3/2024 09:09 | Lovely to see these break above £17 now, next step £18 hopefully in the next couple of months... | ![]() igoe104 | |
07/3/2024 07:35 | GSK announces positive results from DREAMM-8 phase III trial for Blenrep versus standard of care combination in relapsed/refractory multiple myeloma | ![]() panache1 | |
07/3/2024 07:12 | Good RNS this morning positive news should be positive for the share price | ![]() evianone | |
06/3/2024 12:08 | Only news I can see is the WHO saying resistance to GSK's drug dolutegravir has exceeded levels observed during trials | ![]() dplewis1 | |
06/3/2024 11:13 | Why the drop today | ![]() mj19 | |
04/3/2024 14:19 | On Monday, Guggenheim Securities adjusted its stance on shares of GlaxoSmithKline (NYSE:GSK), upgrading the stock from Neutral to Buy. The firm's decision follows recent updates on the company's revenue and a growing confidence in the potential for margin benefits. The firm has set a price target for GlaxoSmithKline at £20.31 per share, which represents a 22% potential increase from the last closing price. | tradermichael |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions